Cascadian Therapeutics’ (CASC) Buy Rating Reiterated at Cowen and Company

Cowen and Company reaffirmed their buy rating on shares of Cascadian Therapeutics Inc. (NASDAQ:CASC) in a research note published on Monday.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research raised Cascadian Therapeutics from a hold rating to a buy rating and set a $2.00 target price for the company in a research note on Tuesday, October 4th. Cantor Fitzgerald reissued a hold rating and set a $2.00 target price on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. Finally, Jefferies Group reissued a buy rating on shares of Cascadian Therapeutics in a research note on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $3.20.

Cascadian Therapeutics (NASDAQ:CASC) opened at 1.33 on Monday. The firm’s 50-day moving average price is $1.34 and its 200-day moving average price is $1.18. Cascadian Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.75. The firm’s market cap is $179.96 million.

Cascadian Therapeutics (NASDAQ:CASC) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.14. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. On average, equities research analysts anticipate that Cascadian Therapeutics will post $5.02 earnings per share for the current year.

In other news, insider Scott Dunseth Myers acquired 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was purchased at an average cost of $1.15 per share, with a total value of $51,750.00. Following the purchase, the insider now directly owns 107,500 shares of the company’s stock, valued at approximately $123,625. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 19.40% of the stock is owned by corporate insiders.

About Cascadian Therapeutics

Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.

5 Day Chart for NASDAQ:CASC

Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.